Faculty

Institution

Unit

Venue

Joseph Uberti

Professor

Wayne State University

Affiliations

School of Medicine

Oncology

Joseph Uberti is currently serving as an Oncology Professor at Wayne State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Joseph Uberti

Wayne State University

Professor

You can click a keyword to filter the displayed items

hematology medicine cell transplantation transplantation medicine immunology clinical transplantation bone marrow transplantation stem cell transplantation regenerative medicine oncology organ transplantation cellular therapy dermatology pharmacology immunotherapy cell therapy medicinal research stem cells hematological malignancies cancer treatment clinical research cancer care cancer research graft survival graft rejection lymphoid neoplasia leukemia transplant surgery multiple myeloma stem-cell therapy pharmacotherapy stem cell research liver transplantation transplantation proceeding stem cell mobilization experimental medicine cancer immunosurveillance cancer management transplant infectious diseases clinical immunology immunomodulation acute graft-versus-host disease therapeutic vaccines surgical oncology cancer biology myelodysplastic syndrome respiratory medicine medical virology cellular immune responses pleural effusion graft-versus-host disease myelodysplastic syndromes adoptive immunotherapy chronic gvhd risk factors gvhd prophylaxis therapeutic efficacy metronomic therapy clinical mycology patient-reported outcomes treatment development chronic graft-versus-host disease primary treatment mesenchymal stem cells health outcomes immunohaematology disease risk assessment adaptive immune system disease prevention treatment effects novel therapies idiopathic pneumonia syndrome nephrotic syndrome busulfan-based regimens preclinical studies autologous transplantation pathology radiation oncology malignant hematology bone marrow transplant

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract Ct151: Trial in Progress: A Phase 1 Trial of Tsc-100 and Tsc-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation. Cancer Research (2024)

Monzr Al MalkiAlla KeyznerHyung SuhUday PopatChen Yi-BinSaar GillMelhem SolhJoseph UbertiIris IsufiErica BuonomoYun WangJim MurrayGavin MacBeathDebora BartonShrikanta ChattopadhyayRan Reshef

cancer immunotherapycancer biologypharmacologycell transplantationminor histocompatibilitycellular therapyoncologycancer researchcancer carebiomedical engineeringcancer treatmentclinical immunologyresidual diseaseclinical trialsclinical transplantationimmunologymedicinal researchhematopoietic cell transplantationcell therapycancer managementclinical research

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial. medRxiv (2024)

Jason G. DehnBrent LoganBronwen E. ShawSteven DevineStefan O. CiureaMary HorowitzNaya HeIskra PusicSamer A. SrourSally AraiMark JuckettJoseph UbertiLaQuisa HillSumithira VasuWilliam J. HoganBrandon Hayes-LattinPeter WesterveltAsad BasheyNosha FarhadfarMichael R. GrunwaldEric LeiferHeather SymonsAyman SaadJenny VogelConnor EricksonKelly BuckStephanie J. LeeJoseph Pidala

interventional trialmedicineregenerative medicineimmunologycell transplantationdonor search prognosistransplantation medicine

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates Across Donor Search Prognosis Groups: A Report From the Bmt Ctn 1702 Trial. Transplantation and Cellular Therapy (2024)

Joseph A. PidalaBrent LoganNaya HeStephanie J LeeStefan O. CiureaSteven M. DevineBronwen E. ShawJenny VogelConnor EricksonAsad BasheyJerry DoyleNancy DiFronzoNosha FarhadfarMike R. GrunwaldBrandon Hayes-LattinLori HendersonWilliam J. HoganMary M. HorowitzEric LeiferHeather SymonsDr. Iskra PusicSamer A. SrourSally AraiMark JuckettDianna S. HowardJoseph UbertiLaQuisa Chimere HillSumithira VasuJason Dehn

comparable transplant ratesdonor searchselection strategyhealth sciencesclinical trials

Haploidentical vs. Mismatched Unrelated Donor Transplants With Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis. Bone Marrow Transplantation (2024)

Dipenkumar ModiSeongho KimMaya ShattaAbhinav DeolAndrew KinLois AyashVoravit RatanatharathornJoseph P. Uberti

hematologyorgan transplantationclinical transplantationorthopaedic surgerybone marrow transplantationtransplant surgeryregenerative medicineunrelated donor transplantstransplantation medicine

Likelihood of Finding an 8/8 Hla-Matched Unrelated Donor (Donor Search Prognosis) is Not Associated With Survival: Primary Results From Bmt Ctn 1702. Blood (2024)

Stephanie J. LeeBrent R. LoganMary M. HorowitzPeter WesterveltWilliam J. HoganJoseph A. PidalaJason DehnBrandon Hayes-LattinNosha FarhadfarAsad BasheyMichael R. GrunwaldSamer A. SrourClaudio BrunsteinHeather Jill SymonsJoseph UbertiIskra PusicEric LeiferNaya HeSteven M. DevineBronwen E. ShawStefan O. Ciurea

hematologygraft survivalblood transfusionbiostatisticsblood donationgraft rejectionsurvival analysishla-matched unrelated donorhla typingdonor search prognosis

Prognostic Understanding for Older, Medically Infirm, and/or Frail Recipients of Allogeneic Hematopoietic Cell Transplantation in an Ongoing Seamless Phase 2/3 Randomized Interventional Trial (Ace-Bmt). Blood (2024)

Elizabeth T. LoggersJames FaustoMatthew GivensMei-Ean YeowReena V. JayaniHassan B AlkhateebLaura A SchoenherrMichael W. RabowMark B JuckettGeorge CarrumJoseph UbertiKyle NealeSantiago LopezDiana Martins-WelchJeanette G FerrerLaura S RheeDrew A RosielleSusan McInnesJason A WebbRachel J. CookElisheva NewmanRonald SobecksLaura JohnstonMohamed Sorror

hematologyinterventional trialtranslational medicinemedicineclinical transplantationgraft survivaloncologyprognostic evaluationbone marrow transplantationprognostic understandingearly diagnosiscell transplantationcritical carestem cell transplantationemergency medicinetransplantation medicineclinical trials

The Composite Health Risk Assessment Model (Charm) Predicts Risks of Toxicities, Functional and Cognitive Decline Among Survivors of Allogeneic Hematopoietic Cell Transplantation (Allo-Hct): A Prospective Bmt-Ctn Study 1704. Blood (2024)

Mohamed SorrorWael SaberBrent R. LoganNancy GellerAnna BellachJianqun KouWilliam A. WoodJohn M. McCartyThomas G. KnightLyndsey RunaasLaura JohnstonJeremy WalstonRyotaro NakamuraAsmita MishraJoseph UbertiParastoo B DahiJennifer N. SaultzShannon R McCurdyLawrence E MorrisPhilip ImusWilliam J. HoganKalyan NadimintiVijaya Raj BhattRebecca OlinJoseph E. MaakaronRonald SobecksSarah A. WallDeborah MattilaBailey ProtzSteven M. DevineMary M. HorowitzAndrew Artz

global healthhematologyclinical transplantationgraft survivalcohort studiesclinical epidemiologyhealth effectsbone marrow transplantationcognitive declinecell transplantationrisk managementhealth outcomespublic healthpatient safetysurvival analysisdisease risk assessmentepidemiology

Tsc-100 and Tsc-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients With Aml, All, or Mds Undergoing Allogeneic Hct With Reduced Intensity Conditioning (Ric): Preliminary Results From the Phase 1 Alloha Trial. Blood (2024)

MHD Monzr M. Al MalkiAlla KeyznerUday PopatYi-Bin ChenHyung C SuhTania JainMelhem M. SolhAnson SnowSaar GillLohith GowdaJoseph UbertiErica BuonomoYun WangNancy NabilsiTimothy WhiteCuong NguyenJim MurrayGavin MacBeathChrystal LouisShrikanta ChattopadhyayMichelle MatzkoRan Reshef

relapse-free survivalhematologyrelapse preventionmedicinerelapse ratesalloha trialreduced intensity conditioning

Acute Leukemia and Mds Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those With 60-69 Years of Age. Blood (2023)

Asmita ShuklaSeongho KimHyejeong JangAndrew KinAasiya MatinLois AyashAbhinav DeolVoravit RatanatharathornJoseph UbertiDipenkumar Modi

hematologymedicineoncologygeriatricsinferior survivalgeriatric medicinemds patientsacute leukemiasurvival analysisclinical gerontologyemergency medicine

Allogeneic Stem Cell Transplant Outcomes Between Tbi-Containing Reduced Intensity and Myeloablative Conditioning Regimens for All in Complete Remission. Leukemia & lymphoma/Leukemia and lymphoma (2023)

Dipenkumar ModiSamer AlkassisSeongho KimAndrew KinAbhinav DeolLois AyashVoravit RatanatharathornJoseph P. Uberti

cancer immunotherapyorgan transplantationmedicineleukemiacell transplantationcellular therapyoncologycancer carecancer treatmentstem cell transplantationtreatment optionsimmunologymedicinal researchcomplete remissionregenerative medicinemyeloablative conditioning regimensoutcomes researchhealth sciencestransplantation medicine

1
2
3
4
5
24
10 / page

Joseph Uberti

Professor

Wayne State University

Affiliations

School of Medicine

Oncology

Joseph Uberti is currently serving as an Oncology Professor at Wayne State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Joseph Uberti

Wayne State University

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Monzr Al MalkiAlla KeyznerHyung SuhUday PopatChen Yi-BinSaar GillMelhem SolhJoseph UbertiIris IsufiErica BuonomoYun WangJim MurrayGavin MacBeathDebora BartonShrikanta ChattopadhyayRan Reshef

Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: An Interventional Trial. medRxiv (2024)

interventional trialmedicineregenerative medicineimmunologycell transplantationdonor search prognosistransplantation medicine

Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates Across Donor Search Prognosis Groups: A Report From the Bmt Ctn 1702 Trial. Transplantation and Cellular Therapy (2024)

comparable transplant ratesdonor searchselection strategyhealth sciencesclinical trials

Haploidentical vs. Mismatched Unrelated Donor Transplants With Posttransplant Cyclophosphamide-Based Gvhd Prophylaxis. Bone Marrow Transplantation (2024)

Dipenkumar ModiSeongho KimMaya ShattaAbhinav DeolAndrew KinLois AyashVoravit RatanatharathornJoseph P. Uberti

hematologyorgan transplantationclinical transplantationorthopaedic surgerybone marrow transplantationtransplant surgeryregenerative medicineunrelated donor transplantstransplantation medicine

Likelihood of Finding an 8/8 Hla-Matched Unrelated Donor (Donor Search Prognosis) is Not Associated With Survival: Primary Results From Bmt Ctn 1702. Blood (2024)

hematologygraft survivalblood transfusionbiostatisticsblood donationgraft rejectionsurvival analysishla-matched unrelated donorhla typingdonor search prognosis

relapse-free survivalhematologyrelapse preventionmedicinerelapse ratesalloha trialreduced intensity conditioning

Acute Leukemia and Mds Patients Older Than 70 Years Have Inferior Survival Following Allogeneic Stem Cell Transplant Compared to Those With 60-69 Years of Age. Blood (2023)

Asmita ShuklaSeongho KimHyejeong JangAndrew KinAasiya MatinLois AyashAbhinav DeolVoravit RatanatharathornJoseph UbertiDipenkumar Modi

hematologymedicineoncologygeriatricsinferior survivalgeriatric medicinemds patientsacute leukemiasurvival analysisclinical gerontologyemergency medicine

Dipenkumar ModiSamer AlkassisSeongho KimAndrew KinAbhinav DeolLois AyashVoravit RatanatharathornJoseph P. Uberti

1
2
3
4
5
24
10 / page

Similar Faculty Members

Lois Ayash

Institution

Wayne State University

hematology

radiation oncology

Brenda W. Cooper

Institution

Case Western Reserve University

medicine

hematology

Elizabeth Hexner

Institution

University of Pennsylvania

hematology

medicine

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine

Anita D'Souza

Institution

Medical College of Wisconsin

psychiatry

hematology

Edward Stadtmauer

Institution

University of Pennsylvania

bone marrow transplantation

acute myeloid leukemia

David L. Porter

Institution

University of Pennsylvania

hematology

medicine

Selina M. Luger

Institution

University of Pennsylvania

hematology

medicine

Stephen J. Schuster

Institution

University of Pennsylvania

oncology

medicine

Brenda M. Sandmaier

Institution

University of Washington

graft rejection

graft-vs.-host disease

Similar Faculty Members

Lois Ayash

Institution

Wayne State University

hematology

radiation oncology

Brenda W. Cooper

Institution

Case Western Reserve University

medicine

hematology

Elizabeth Hexner

Institution

University of Pennsylvania

hematology

medicine

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine

Anita D'Souza

Institution

Medical College of Wisconsin

psychiatry

hematology

Edward Stadtmauer

Institution

University of Pennsylvania

bone marrow transplantation

acute myeloid leukemia

David L. Porter

Institution

University of Pennsylvania

hematology

medicine

Selina M. Luger

Institution

University of Pennsylvania

hematology

medicine

Stephen J. Schuster

Institution

University of Pennsylvania

oncology

medicine

Brenda M. Sandmaier

Institution

University of Washington

graft rejection

graft-vs.-host disease